River Street Advisors LLC Purchases 65 Shares of Danaher Co. (NYSE:DHR)

River Street Advisors LLC lifted its position in Danaher Co. (NYSE:DHR) by 2.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,486 shares of the conglomerate’s stock after acquiring an additional 65 shares during the period. River Street Advisors LLC’s holdings in Danaher were worth $691,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Turtle Creek Wealth Advisors LLC lifted its position in Danaher by 6.4% during the third quarter. Turtle Creek Wealth Advisors LLC now owns 865 shares of the conglomerate’s stock valued at $240,000 after purchasing an additional 52 shares during the period. Natixis Advisors LLC raised its position in Danaher by 5.1% in the third quarter. Natixis Advisors LLC now owns 802,429 shares of the conglomerate’s stock worth $223,091,000 after acquiring an additional 39,029 shares during the period. Ipswich Investment Management Co. Inc. raised its position in Danaher by 1.4% in the third quarter. Ipswich Investment Management Co. Inc. now owns 6,008 shares of the conglomerate’s stock worth $1,670,000 after acquiring an additional 82 shares during the period. First Long Island Investors LLC increased its stake in shares of Danaher by 1.4% in the third quarter. First Long Island Investors LLC now owns 55,651 shares of the conglomerate’s stock worth $15,472,000 after purchasing an additional 755 shares in the last quarter. Finally, Simplify Asset Management Inc. increased its stake in shares of Danaher by 66.3% in the third quarter. Simplify Asset Management Inc. now owns 2,072 shares of the conglomerate’s stock worth $576,000 after purchasing an additional 826 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research reports. TD Cowen increased their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Raymond James lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Stock Performance

NYSE DHR traded down $8.88 during trading hours on Friday, reaching $230.50. The stock had a trading volume of 5,435,775 shares, compared to its average volume of 2,760,084. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a fifty day moving average of $262.20 and a 200 day moving average of $260.38. Danaher Co. has a 52-week low of $206.30 and a 52-week high of $281.70. The stock has a market cap of $166.49 billion, a P/E ratio of 43.99, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 EPS. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. Sell-side analysts predict that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.